<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Neil M Ampel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janis E Blair, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H881899422"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with impaired cellular immunity are at increased risk for severe or disseminated infection. In these patient populations (eg, patients with HIV and a CD4 count &lt;250 cells/microL, those undergoing transplant, patients initiating tumor necrosis factor inhibitor [TNFi] treatment), certain management aspects should be considered when treating these patients for coccidioidomycosis. In addition, screening for asymptomatic infection is warranted so that antifungal therapy can be administered to reduce the risk of developing symptomatic disease. </p><p>This topic will review the principles and strategies of treating coccidioidomycosis and reducing the risk of coccidioidomycosis in patients during pregnancy and/or with immunocompromising conditions. Specifically, we discuss patients with HIV, transplant recipients, and patients receiving immunomodulating therapies. </p><p>The antifungal selection in the treatment of coccidioidomycosis in immunocompromised patients is similar to that for immunocompetent patients and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Immunocompromised patients'</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis", section on 'Management'</a>.)</p><p>The main discussions on clinical manifestations, diagnosis, and management of pulmonary and extrapulmonary coccidioidomycosis are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a> and  <a class="medical medical_review" href="/z/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening"</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a> and  <a class="medical medical_review" href="/z/d/html/2445.html" rel="external">"Coccidioidal meningitis"</a>.)</p><p class="headingAnchor" id="H608548559"><span class="h1">MANAGEMENT CONSIDERATIONS FOR SPECIAL POPULATIONS</span><span class="headingEndMark"> — </span>Patients with impaired cellular immunity and those who are pregnant warrant extra consideration in management of coccidioidomycosis. </p><p class="headingAnchor" id="H2158955020"><span class="h2">Immunocompromised patients</span><span class="headingEndMark"> — </span>Cellular immunity is critical to the control of coccidioidomycosis [<a href="#rid1">1</a>]. Animal studies have been supported by clinical observations demonstrating more severe and/or disseminated coccidioidal disease among patients with advanced HIV infection [<a href="#rid2">2</a>], those with solid organ transplants [<a href="#rid3">3</a>], and those receiving anticytokine therapy [<a href="#rid4">4</a>]. Within the UpToDate topics on coccidioidomycosis, use of the term "immunosuppression" or "immunocompromise" refers to depressed cellular immunity and not to depressed humoral immunity. </p><p>Immunocompromised patients include: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV and CD4 cell counts &lt;250 cells/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplant recipients who are on immunosuppression</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving TNF-alpha inhibitors, high-dose glucocorticoids, and certain other immunomodulators </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with solid tumor malignancies who are receiving lymphodepleting chemotherapy [<a href="#rid5">5</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with active hematologic malignancies, as well as those in remission because severe illness has been reported in such patients even after completion of chemotherapy and radiation therapy [<a href="#rid6">6</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chimeric antigen receptor (CAR)-T cell therapy recipients [<a href="#rid7">7</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with specific gene mutations (interferon gamma receptor [IFN-gammaR1], IL-12 receptor [IL-12Rbeta1] [<a href="#rid8">8</a>], STAT1 [<a href="#rid9">9</a>], and STAT3 [<a href="#rid10">10</a>])</p><p></p><p class="headingAnchor" id="H571016659"><span class="h3">Key differences in management of immunocompromised patients</span><span class="headingEndMark"> — </span>Patients with impaired cellular immunity are at increased risk for severe disease, dissemination, and reactivation of infection. The general principles of management of coccidioidomycosis in the immunocompromised host  (<a class="graphic graphic_table graphicRef121808" href="/z/d/graphic/121808.html" rel="external">table 1</a>) are the same as those for the normal host, but there are a few major differences:</p><p class="bulletIndent1"><span class="glyph">●</span>All immunocompromised patients with clinically active coccidioidomycosis at any anatomic site should receive antifungal therapy because of their high risk for both severe disease and extrathoracic dissemination. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antifungal therapy is generally prolonged and often lifelong in those who remain immunocompromised. (See <a class="local">'Duration of therapy'</a> below and <a class="local">'Secondary prevention'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minimizing immunosuppression and improving cellular immunity in an immunocompromised patient is a key part of coccidioidomycosis therapy. In patients with HIV, this means initiation of ART as soon as safely possible and monitoring the patient closely for adherence and complications. In patients on immunosuppressive drugs (eg, transplant recipients), this means reduction in dose or complete discontinuation of immunosuppressants, when possible. Patients with specific gene mutations generally require prolonged antifungal therapy and, if possible, immune modulation therapy to overcome the genetic defect.</p><p></p><p>All such cases should be managed in conjunction with an infectious diseases expert who is experienced in the treatment of coccidioidomycosis.</p><p class="headingAnchor" id="H1691110648"><span class="h3">Patients with HIV</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines%2Fhiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections%2Fcoccidioidomycosis%3Fview%3Dfull&amp;token=oQS3HKezOmJzSZ2AgVZe1oPEN1wfrauBzMVSQxjAf1bCcey2waHss2sUndvNNOXAqdasN5YpMESUYe0zXXto6F4pcrQLHgO64bILAb%2F4sLzHegDBXXfKyKdVpcm%2BUDJEyKVv%2BZkoBI3cDPCUsds%2BEQ%3D%3D&amp;TOPIC_ID=2418" target="_blank">United States Department of Health and Human Services</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fcid%2Farticle%2F63%2F6%2Fe112%2F2389093%3Flogin%3Dtrue&amp;token=VHIihOfc3yKXOhtg%2FRL%2FfBs1oYEdOIZ8aP%2BRXPzKmWm61uMJAWyxwcI7G%2FzsuJV50oTalsMt829TgGHUcaeizIbUPxbW65dyVQQbAq0gLAg%3D&amp;TOPIC_ID=2418" target="_blank">Infectious Diseases Society of America</a> both have sections on coccidioidomycosis management in patients with HIV [<a href="#rid11">11,12</a>]. Our recommendations are generally in keeping with these guidelines. Most cases identified within coccidioidal-endemic areas appear to be due to recent acquisition, although it can occasionally be due to reactivation of previously acquired infection [<a href="#rid13">13,14</a>]. </p><p class="headingAnchor" id="H2752145106"><span class="h4">Role of CD4 count and antiretroviral therapy</span><span class="headingEndMark"> — </span>A low peripheral blood CD4 lymphocyte count (CD4 cell count &lt;250 cells/microL), and hence a reduced cellular immune function, is the most important factor in determining whether a person with HIV will develop symptomatic coccidioidomycosis following exposure [<a href="#rid15">15</a>]. </p><p>Management of coccidioidomycosis in persons with HIV depends upon immune status and the severity of disease. The basic principles of managing coccidioidomycosis in persons with HIV are summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CD4 cell counts ≥250 cells/microL, management should be the same as in healthy patients without underlying immunodeficiency. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Immunocompetent nonpregnant patients'</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis", section on 'Approach to treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CD4 cell counts &lt;250 cells/microL, antifungal therapy should be initiated and continued for the duration of treatment <strong>and </strong>until the CD4 cell count is ≥250 cells/microL and viral load is suppressed for at least three months. (See <a class="local">'Secondary prevention'</a> below.)</p><p></p><p>In a prospective cohort study performed in the era before the introduction of potent combination antiretroviral therapy (ART), approximately 25 percent of persons with HIV living in an endemic region developed symptomatic coccidioidomycosis [<a href="#rid2">2</a>], and the main risk factor was a CD4 count &lt;250 cells/microL or a clinical diagnosis of AIDS. Lack of in vitro response to coccidioidal antigen and presumed lack of protective immunity have been found to be associated with a CD4 cell count of &lt;250 cells/microL [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H53824850"><span class="h4">Initiating antiretroviral therapy</span><span class="headingEndMark"> — </span>In general, we initiate antiretroviral therapy (ART) in newly diagnosed patients with HIV and CD4 cell count ≥250 cells/microL with coccidioidomycosis as soon as possible. In those with active coccidioidomycosis who are diagnosed coincidently with HIV and in whom the CD4 cell count is &lt;250 cells/microL, it may be prudent to start antifungal therapy four to eight weeks prior to initiating ART, particularly in those with coccidioidal meningitis. All such patients should be closely monitored. </p><p>The use of potent combination ART, which results in virologic suppression, increased CD4 cell counts, and immune restoration, has decreased the incidence of symptomatic coccidioidomycosis in persons with HIV and is the most important factor in preventing and treating symptomatic coccidioidomycosis in persons with HIV [<a href="#rid16">16-18</a>]. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p class="headingAnchor" id="H1469772775"><span class="h4">Immune reconstitution inflammatory syndrome</span><span class="headingEndMark"> — </span>Instances of immune reconstitution inflammatory syndrome (IRIS) have been reported in patients with coccidioidomycosis [<a href="#rid19">19-23</a>]. Most patients have had active coccidioidomycosis at the time of initiation of ART and all had CD4 cell counts &lt;150 cells/microL. In several cases, patients developed worsening coccidioidomycosis despite being on both antifungal therapy and ART [<a href="#rid19">19,22</a>], suggesting that such patients should be closely monitored. </p><p>There are scant data on the most appropriate way to manage a person with HIV and IRIS due to coccidioidomycosis. We continue both antifungal therapy and ART and consider adding corticosteroids, although there is a lack of data on the latter. A more detailed discussion of IRIS is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H4073211273"><span class="h3">Patients taking immunomodulatory agents</span><span class="headingEndMark"> — </span>Patients receiving antagonist therapy against tumor necrosis factor-alpha inhibitors (TNFi) are at increased risk for symptomatic and disseminated coccidioidomycosis [<a href="#rid4">4</a>]. For other anti-cytokine and related therapies, the risk is far less clear and is discussed elsewhere. (See <a class="local">'Indications for screening'</a> below.) </p><p>In cases of symptomatic coccidioidomycosis, we withhold TNFi for at least six weeks and simultaneously initiate antifungal treatment  (<a class="graphic graphic_table graphicRef121808" href="/z/d/graphic/121808.html" rel="external">table 1</a>) because of the risk of severe disease and possible dissemination [<a href="#rid4">4,24</a>]. If after six weeks, the patient has clinically improved, it may be reasonable to restart TNFi therapy. </p><p class="headingAnchor" id="H4255140635"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>Immunosuppressed patients may improve more slowly and require longer treatment durations than nonimmunosuppressed individuals. The duration of treatment ultimately depends on the clinical, serologic, and radiographic responses as well as the severity and duration of the cellular immunosuppression. We look for resolution of symptoms, significant improvement in radiographic findings, and a complement-fixation serology titer of ≤1:4. In general, we treat patients with pulmonary coccidioidomycosis for at least 6 to 12 months and extrapulmonary disseminated disease for at least 12 months, but longer courses may be required. In some cases in which immunosuppression is persistent, lifelong therapy may be appropriate. </p><p>After completion of therapy, patients should continue to receive secondary prophylaxis to prevent recrudescence of infection while they remain on immunosuppressive therapy. (See <a class="local">'Secondary prevention'</a> below.)</p><p class="headingAnchor" id="H1771279294"><span class="h3">Secondary prevention</span><span class="headingEndMark"> — </span>Due to the risk of reactivation, secondary prevention is beneficial for patients who have completed treatment for coccidioidomycosis but remain immunocompromised, such as patients with HIV and CD4 cell count &lt;250 cells/microL or patients who continue taking immunosuppressive agents. We typically decrease the <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> dose to 200 mg orally daily for secondary prevention. If patients are taking other oral azoles, a decision should be made with the patient regarding whether to switch to fluconazole or continue the other azole. </p><p>We continue secondary prevention until the patient is no longer immunocompromised. In some individuals, this may mean lifelong antifungal therapy. </p><p>In patients with impaired cellular immunity, there are no data to guide the duration of monitoring after the initial few years. We perform a coccidioidal serology and appropriate imaging annually for as long as the immunosuppression continues. </p><p class="headingAnchor" id="H2424675245"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>There are several important issues surrounding coccidioidomycosis and pregnancy [<a href="#rid25">25</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serologic screening</strong> – We do not routinely serologically screen pregnant individuals who reside in a coccidioidal-endemic region, regardless of whether they previously had coccidioidomycosis [<a href="#rid26">26,27</a>]. Pregnant females who have acquired infection prior to pregnancy generally control their infection and do not require therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment </strong>– The decision to treat pregnant females with evidence of active coccidioidomycosis depends on the stage of pregnancy and the manifestations of coccidioidal illness. Management of pregnant patients with coccidioidomycosis should be done in consultation with an expert in coccidioidomycosis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe and/or extrathoracic disease</strong> – Treatment is indicated for all pregnant females with <strong>severe </strong>and/or <strong>extrathoracic</strong> infection. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild or moderate pulmonary disease</strong> – For pregnant individuals with mild to moderate coccidioidomycosis, clinicians should engage in shared decision-making with their patients after discussing risks and benefits of initiating therapy. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Females in their first trimester of pregnancy who present with<strong> mild to moderate primary pulmonary</strong> disease or<strong> a positive coccidioidal serology without clinical illness </strong>typically do not require antifungal therapy. In such cases, careful clinical monitoring with clinical evaluation and serology every 6 to 12 weeks is appropriate. Increasing titers are concerning for more active disease and warrant further discussion with the patient regarding initiating therapy. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals who acquire coccidioidomycosis during second or third trimester or within six weeks postpartum are at increased risk for developing severe or disseminated disease during that period and should be followed very closely [<a href="#rid25">25,28</a>]. Decision to initiate treatment in these patients is made on a case-by-case basis, taking into account the patient's preferences, the severity of the symptoms, the risk of azoles to the fetus, and the trajectory of the coccidioidal antibody titer, and should be done in consultation with an expert in coccidioidomycosis. </p><p></p><p class="bulletIndent1">For females who are receiving azole antifungal treatment for coccidioidomycosis when they become pregnant, we discontinue the azole and initiate amphotericin B for the duration of the first trimester. We also obtain new baseline serologic testing and perform a clinical evaluation every 6 to 12 weeks to monitor clinical status and progression. Nonpregnant females with active coccidioidomycosis who are on triazole antifungal therapy should be advised to consider foregoing pregnancy while on therapy and to consider, if possible, stopping therapy prior to becoming pregnant.</p><p></p><p class="bulletIndent1">Pregnant females with coccidioidomycosis should be managed in conjunction with an infectious diseases specialist. </p><p></p><p class="bulletIndent1">The fetus and newborn are rarely affected by maternal coccidioidomycosis [<a href="#rid29">29</a>]. IgG coccidioidal antibody may be detected in the serum of newborns of mothers with recent infection. This is usually a result of passive transfer of maternal antibody and in itself does not indicate infection [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/4988.html" rel="external">"Unusual fungal infections in the neonate", section on 'Coccidioidomycosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal selection </strong>– Triazole antifungals should be avoided during the first trimester of pregnancy given the potential risk of teratogenicity [<a href="#rid31">31-33</a>] as well as spontaneous abortion and stillbirth [<a href="#rid34">34,35</a>]. This may require the use of intravenous amphotericin B in those with active nonmeningeal coccidioidomycosis and intrathecal amphotericin B in those with active meningeal coccidioidomycosis during this period.</p><p></p><p class="bulletIndent1">After the first trimester, it may be reasonable to initiate a triazole antifungal, but this should be done on a case-by-case basis after careful consultation with the patient, obstetrician, and infectious diseases expert. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Pregnancy'</a>.)</p><p></p><p class="headingAnchor" id="H3249061256"><span class="h1">SCREENING AND PREVENTION IN IMMUNOCOMPROMISED INDIVIDUALS</span></p><p class="headingAnchor" id="H4191159234"><span class="h2">Reducing environmental exposure</span><span class="headingEndMark"> — </span>It is impossible to completely avoid exposure to coccidioidomycosis in the endemic area because the fungus is frequently present in ambient air [<a href="#rid36">36</a>]. However, we do counsel at-risk patients to stay inside during dust storms and avoid activities that result in exposure to local dust or desert soil. Patients visiting these areas should also be educated about the use of these precautions. With specific exceptions noted below (solid organ transplantation, hematopoietic cell transplantation), we do not routinely recommend the use of long-term antifungal prophylaxis for the primary prevention of coccidioidomycosis, as this has not been found to be effective [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H3045933955"><span class="h2">Approach to serologic screening</span><span class="headingEndMark"> — </span>Serologic tests are used for screening for coccidioidomycosis. Several different serologic tests are available. Enzyme-linked immunoassays (EIAs) for immunoglobulin M (IgM) and IgG detection are widely available and have high sensitivity but are not as specific as immunodiffusion (ID; detecting IgM and IgG) and complement-fixation (CF; detecting IgG) serologic tests, which are only found in certain reference laboratories. EIA IgM, in particular, is very prone to false-positive results, especially when screening for infection in the absence of symptoms. Hence, every positive EIA IgM serology must be confirmed by a positive EIA IgG or a positive immunodiffusion and CF test. </p><p>There are two approaches to using serologic tests for screening: </p><p class="bulletIndent1"><span class="glyph">●</span>One of the authors orders the EIA first and only proceeds with ordering the ID and CF tests if the EIA is positive. This approach is a cost-effective and appropriate option for screening populations at low risk for coccidioidal disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, the other author orders both the EIA and the ID and CF tests at the same time to obtain the most information regarding current or past evidence of coccidioidomycosis. This approach allows for detection of the small percentage of patients who may have a negative EIA but positive ID and/or CF titer.</p><p></p><p>Serologic testing is combined with a clinical and radiographic evaluation for symptoms and/or signs of active or remote coccidioidal disease. Presence of symptoms, signs, or radiographic abnormalities suggestive of a pulmonary infection in the setting of negative coccidioidal serology warrants further evaluation (including for coccidioidomycosis), with fluid or tissue sample collection that can be sent for culture and histopathology. </p><p class="headingAnchor" id="H1024442222"><span class="h2">Patients with HIV</span><span class="headingEndMark"> — </span>We screen all patients with HIV and a CD4 cell count ≤250 cells/microL who live in endemic areas with coccidioidal serology and chest imaging every six months, usually at the same time as routine HIV RNA and CD4 cell count evaluation. If coccidioidal serology is positive, we initiate pre-emptive therapy with an oral triazole (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg orally daily) and continue therapy until the CD4 cell count is &gt;250 cells/microL and viral load is suppressed for at least three months [<a href="#rid37">37</a>]. In addition, we discuss ways to reduce environmental exposure and emphasize that the use of antiretroviral therapy (ART) is the most effective way to prevent the development of severe coccidioidomycosis. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.) </p><p class="headingAnchor" id="H276989660"><span class="h2">Transplant recipients</span></p><p class="headingAnchor" id="H703829814"><span class="h3">Screening prior to transplantation</span><span class="headingEndMark"> — </span>It is important to identify transplant candidates who may be at risk of reactivating asymptomatic coccidioidal infection post-transplantation or those who may be harboring an asymptomatic infection [<a href="#rid38">38,39</a>]. Because of this, we screen all solid organ and hematopoietic cell transplant candidates if they live in, have lived in, or traveled in an endemic area. We do not typically screen patients who have only temporarily visited endemic areas (eg, one week or less), since the pretest probability of infection is low, and a false-positive test could mean life-long prophylaxis. However, serologic testing should be performed in these low-risk patients if they have symptoms that could be consistent with coccidioidomycosis. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'When to suspect infection'</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis", section on 'Initial evaluation'</a>.)</p><p>Screening involves an assessment for both active and past infection based upon history, serology, and chest radiograph. </p><p>For patients with positive coccidioidal serology and chest radiograph findings and/or symptoms consistent with active coccidioidomycosis, we initiate antifungal therapy and defer transplant until it is clinically evident that the coccidioidal infection is controlled. Transplant can then proceed with the patient continuing treatment post-transplantation. Transplant candidates with positive coccidioidal serology should be managed by an infectious diseases consultant. (See <a class="local">'Immunocompromised patients'</a> above and  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Immunocompromised patients'</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis", section on 'Approach to treatment'</a>.)</p><p>For all other patients without clinical evidence of active coccidioidal disease, such as an asymptomatic patient with isolated positive coccidioidal serology or negative coccidioidal serology, no treatment is necessary until post-transplantation. (See <a class="local">'Preventive therapy in solid organ transplant recipients'</a> below and <a class="local">'Preventive therapy in hematopoietic cell transplant recipients'</a> below.)</p><p class="headingAnchor" id="H1079487080"><span class="h3">Preventive therapy in solid organ transplant recipients</span><span class="headingEndMark"> — </span>We administer preventive therapy post-transplantation to patients at risk for new infection or reactivation, or who received an organ from a donor with coccidioidomycosis [<a href="#rid40">40</a>]. Active coccidioidomycosis can result in serious morbidity and mortality in patients undergoing solid organ transplantation (SOT) [<a href="#rid3">3,39,41-47</a>]. Active disease can result from reactivation of old disease or from primary infection after transplant. The latter is usually related to environmental exposure, but rarely, infection can be transmitted directly from the donor organ [<a href="#rid45">45,47-50</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recipients with negative serology living outside of endemic areas</strong> – Prophylactic antifungal therapy against coccidioidomycosis is not necessary in asymptomatic SOT recipients with negative serology and normal chest imaging who do not reside in coccidioidal-endemic areas, even if they have a remote history of coccidioidomycosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recipients at risk for new infection </strong>– For all SOT recipients who reside in areas that are endemic for <em>Coccidioides</em> species and who are without evidence of remote or active infection (negative history, serology, and chest radiograph), we initiate <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg daily) at the time of transplantation and continue it for 6 to 12 months. </p><p></p><p class="bulletIndent1">This approach to prophylaxis has been shown to markedly reduce the number of new coccidioidal infections in the first post-transplant year in liver transplants [<a href="#rid51">51</a>]. A study in heart transplant patients demonstrated similar findings [<a href="#rid52">52</a>]. In a retrospective study, use of triazole antifungals was associated with a lower risk of coccidioidomycosis among lung transplant recipients living in the coccidioidal-endemic region [<a href="#rid53">53</a>], and a study of universal long-term triazole antifungals, mostly <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, in another group of lung transplant recipients from the endemic region was associated with only one case of active coccidioidomycosis among 493 cases [<a href="#rid40">40,54</a>]. Recently, it has been noted that universal antifungal prophylaxis to prevent coccidioidomycosis in SOT may result in an increased risk of candidiasis due to species other than <em>C. albicans</em> [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recipients at risk for reactivation from latent or subclinical disease </strong>– Patients at risk for reactivation are asymptomatic patients who either have a positive coccidioidal serology and a negative chest radiograph at the time of transplantation or have a recent (eg, within the last two years) diagnosis of coccidioidomycosis with evidence of a pulmonary nidus (eg, nodule) on imaging but with negative coccidioidal serology. Unlike many other infections, a positive coccidioidal serology is not an indication of protection and indicates some degree of ongoing disease activity, even in the absence of symptoms. For these patients, we administer one year of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> at a dose of 400 mg daily and then reduce the dose to 200 mg daily. Although the optimal duration for ongoing prophylaxis is unknown, we continue treatment while the patient remains on immunosuppressive therapy. (See <a class="local">'Secondary prevention'</a> above.)</p><p></p><p class="bulletIndent1">Our approach is based upon our experience with patients undergoing liver, pancreas, kidney, and/or heart transplant [<a href="#rid45">45,46,51</a>]. In a retrospective study of patients undergoing SOT at the authors' center, 44 were identified as having a history of and/or serologic evidence of prior coccidioidal infection without evidence of active disease [<a href="#rid46">46</a>]. Of these, 37 received <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> following transplantation and none had evidence of reactivated infection; the remaining 7 either did not receive postoperative fluconazole or were not adherent to treatment, and 2 had reactivation of coccidioidomycosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recipients who receive an organ from a donor with evidence of coccidioidomycosis </strong>– There have been several reports of coccidioidomycosis transmission from a donor after SOT [<a href="#rid48">48,49,56</a>]. We treat recipients who receive an organ from a donor with evidence of coccidioidomycosis at the time of transplant with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg daily for at least a year, and possibly for life. Since there are no data to guide this decision, the ultimate duration must be made on a case-by-case basis. </p><p></p><p class="headingAnchor" id="H2537695843"><span class="h3">Preventive therapy in hematopoietic cell transplant recipients</span><span class="headingEndMark"> — </span>The indications for and duration of preventive therapy against coccidioidomycosis in hematopoietic cell transplant (HCT) recipients are outlined below. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients living in endemic areas</strong> – For patients living in endemic areas, we administer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg daily for two years regardless of serology based on prior studies indicating a high mortality in those who develop coccidioidomycosis [<a href="#rid39">39,57-59</a>]. Other triazole antifungals can be considered based on availability, cost, and toxicity profile.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with negative serology, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> can be stopped after two years. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with positive serology or imaging findings consistent with coccidioidomycosis in patients with history of coccidioidomycosis, we continue <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> while the patient remains on immunosuppressive therapy. (See <a class="local">'Secondary prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients living outside of endemic areas</strong> – For patients who are not living in endemic areas at the time of their transplant but met criteria for coccidioidal screening, prophylaxis depends on serology. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If serology is negative and there is no evidence of coccidioidal infection on imaging, no prophylaxis is needed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If serology is positive or imaging is concerning for residual coccidioidal infection in a patient with a history of coccidioidomycosis, we administer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for at least two years and continue while patient remains on immunosuppressive therapy. (See <a class="local">'Secondary prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H444117389"><span class="h2">Patients receiving immunomodulatory agents</span></p><p class="headingAnchor" id="H851463889"><span class="h3">Indications for screening</span><span class="headingEndMark"> — </span>Immunomodulatory agents vary in the degree and type of immunosuppression they cause. Patients receiving tumor necrosis factor-alpha inhibitors (TNFi) [<a href="#rid4">4</a>] or the janus kinase (JAK) inhibitor <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a> [<a href="#rid60">60</a>] are at increased risk for symptomatic and disseminated coccidioidomycosis [<a href="#rid4">4,60</a>]. </p><p>The risk is far less clear and appears to be low in patients receiving other anti-cytokine and related therapies, such as anti-interleukin (IL)-12 therapy (eg, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>), anti-IL-17 therapy (eg, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> and <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>), and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy (eg, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>). There is also one report of an association of <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> with reactivation of coccidioidal infection [<a href="#rid61">61</a>]. However, based on their mechanism of action, these agents could decrease the immune control of coccidioidomycosis. Caution is advised when using any of these agents, and close monitoring for development or recrudescence of coccidioidomycosis should be implemented. </p><p>Other immunomodulatory agents, such as <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a> or JAK inhibitors besides <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>, have had no reported cases of severe or worsening coccidioidomycosis and do not appear to increase the risk of coccidioidomycosis.</p><p>There is no established guidance for other immunomodulating drugs such as <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>. Although such patients appear to be at increased risk for developing severe coccidioidomycosis [<a href="#rid62">62</a>], there are insufficient data to suggest screening for infection prior to initiating therapy. The approach to each patient should be individualized. </p><p class="headingAnchor" id="H3952645376"><span class="h3">Screening prior to initiating immunomodulators</span><span class="headingEndMark"> — </span>Although we will focus on the approach to management of patients initiating TNFi in this section, other patients at high risk (eg, patients initiating <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>) should follow the same principles. Nevertheless, the approach to each patient should be highly individualized since the data guiding screening and preventive therapy in this patient population are scarce [<a href="#rid4">4,24,62</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening prior to starting immunomodulating therapy</strong> – We screen all patients living or who have lived in coccidioidal-endemic areas for coccidioidomycosis with serology prior to initiating TNFi therapy [<a href="#rid4">4,24,62</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If serology is negative, no preventive therapy is necessary. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the EIA and/or ID serology is positive but CF titer is negative, we evaluate for active infection with a history and physical examination. If there is no evidence of active infection, we start TNFi therapy, hold off on antifungal therapy, and monitor for signs and symptoms of coccidioidomycosis periodically (eg, every 12 weeks) with repeat serology, clinical evaluation, and chest radiograph while the patient remains on immunosuppressive therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the coccidioidal CF titer is ≥1:2, we obtain a chest radiograph and perform a clinical evaluation to assess for symptoms and signs attributable to coccidioidomycosis. If any symptoms or signs consistent with coccidioidomycosis are present, we defer TNFi therapy until treatment for coccidioidomycosis is complete and the patient is asymptomatic (if symptoms were present initially). For patients who are unable to defer TNFi therapy, we start antifungal therapy concurrently with TNFi and monitor clinically with repeat imaging and serology. If there is no evidence of active disease but the titer is positive, we initiate <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and continue the TNFi therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive serology while on immunomodulating therapy</strong> – If a patient is found to have positive coccidioidal serology or an abnormality on pulmonary imaging and is already receiving a TNFi, we assess the patient for symptoms of coccidioidomycosis and monitor the pulmonary infiltrate. If there is evidence of active (symptomatic), progressive (worsening pulmonary infiltrates) disease or if the coccidioidal CF titer is positive (≥1:2), the patient should be started on coccidioidomycosis treatment. If the patient is asymptomatic, we choose not to stop the TNFi; in patients with symptoms of coccidioidomycosis, we stop the TNFi and restart once the symptoms resolve and serology is stabilized. If none of the above are present, the patient can be monitored every three months without starting antifungal therapy.</p><p></p><p>Although screening is commonly performed, the data supporting the usefulness of coccidioidal serologic screening prior to and subsequently after initiating TNFi are conflicting. In a retrospective study evaluating approximately 2000 patients, screening and management of asymptomatic infection prior to initiating TNFi were associated with a lower rate of subsequent symptomatic coccidioidomycosis compared with populations that were not screened (1.3 versus 3.4 percent) [<a href="#rid63">63</a>]. However, in another retrospective study of 19 asymptomatic patients receiving disease-modifying antirheumatic drugs (12 on TNFi) with positive coccidioidal serology, there were no cases of active coccidioidomycosis after medial follow up of 43 months in both the group that received antifungal therapy (6 out of 19) and those who did not (13 out of 19) [<a href="#rid64">64</a>].</p><p>Data concerning <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a> are even more sparse. In a retrospective review of 135 ruxolitinib recipients who resided within the coccidioidal-endemic area, eight (6 percent) patients with coccidioidomycosis were identified, four of whom had multifocal dissemination [<a href="#rid60">60</a>].</p><p>There are no data indicating that other JAK inhibitors (eg, <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>) have the same potential to cause widespread dissemination as <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>. </p><p class="headingAnchor" id="H176096691"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113064.html" rel="external">"Society guideline links: Coccidioidomycosis"</a>.)</p><p class="headingAnchor" id="H474641309"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87358.html" rel="external">"Patient education: Valley Fever (coccidioidomycosis) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9786051"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management considerations in immunocompromised individuals </strong>–<strong> </strong>Cellular immunity is critical to the control of coccidioidomycosis, and patients with impaired cellular immunity are at increased risk for severe and/or disseminated disease. (See <a class="local">'Key differences in management of immunocompromised patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromised patients include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with HIV and CD4 cell counts &lt;250 cells/microL</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Transplant recipients who are on immunosuppression</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients receiving tumor necrosis factor (TNF) alpha inhibitors, high-dose glucocorticoids, and certain other immunomodulators</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with solid tumor malignancies who are receiving lymphodepleting chemotherapy </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with active hematologic malignancies, as well as those in remission since severe illness has been reported, even in such patients after completion of chemotherapy and radiation therapy </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Chimeric antigen receptor (CAR)-T cell therapy recipients </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with specific gene mutations (interferon gamma receptor [IFN-gammaR1], IL-12 receptor [IL-12Rbeta1], STAT1, and STAT3)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All immunocompromised patients with clinically active coccidioidomycosis at any anatomic site should receive antifungal therapy because of their high risk for both severe disease and extrathoracic dissemination. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Immunocompromised patients'</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis", section on 'Approach to treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antifungal therapy is generally prolonged and often lifelong in those who remain immunocompromised. (See <a class="local">'Duration of therapy'</a> above and <a class="local">'Secondary prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimizing immunosuppression and improving cellular immunity in an immunocompromised patient are a key part of coccidioidomycosis therapy. (See <a class="local">'Key differences in management of immunocompromised patients'</a> above and <a class="local">'Role of CD4 count and antiretroviral therapy'</a> above and <a class="local">'Patients taking immunomodulatory agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management considerations in pregnant individuals</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment is indicated for pregnant females with <strong>severe </strong>or <strong>extrathoracic</strong> dissemination of infection. (See <a class="local">'Pregnant patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Triazoles should be avoided during the first trimester of pregnancy given the potential risk of teratogenicity as well as spontaneous abortion and stillbirth. (See <a class="local">'Pregnant patients'</a> above and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and prevention in immunocompromised individuals</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rationale for screening </strong>– Patients with depressed cellular immunity are at increased risk of developing severe and/or disseminated coccidioidomycosis. (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reducing environmental exposure</strong> – It is impossible to completely avoid exposure to coccidioidomycosis in the endemic area because the fungus is frequently present in ambient air. However, we counsel at-risk patients to stay inside during dust storms and avoid activities that result in exposure to local dust or desert soil. (See <a class="local">'Reducing environmental exposure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach to serologic screening </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Various serologic tests are available for screening for coccidioidomycosis. The enzyme immunoassay test is more available and more sensitive; the immunodiffusion (ID) and complement-fixation (CF) tests are more specific but only found in reference laboratories. (See <a class="local">'Approach to serologic screening'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serologic testing is combined with a clinical and radiographic evaluation for symptoms and/or signs of active or remote coccidioidal disease. Presence of symptoms, signs, or radiographic abnormalities suggestive of a pulmonary infection in the setting of negative coccidioidal serology warrants further evaluation (including for coccidioidomycosis), often with fluid or tissue sample collection that can be sent for culture and histopathology. (See <a class="local">'Approach to serologic screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with HIV</strong> – For patients with HIV and CD4 cell count &lt;250 cells/microL who live in endemic areas, we screen for coccidioidomycosis every six months to identify those who need pre-emptive therapy to prevent severe and/or disseminated disease. If coccidioidal serology is positive, we initiate pre-emptive therapy with an oral triazole (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 400 mg orally daily) and continue therapy until CD4 cell count is &gt;250 cells/microL for at least three months. (See <a class="local">'Patients with HIV'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transplant candidates</strong> – For transplant candidates, we screen for all patients who are living, who have lived, or who have traveled extensively (&gt;1 week at a time) in endemic areas. Patients who are found to have active coccidioidal disease should complete antifungal treatment prior to transplant. For patients without active coccidioidal disease, duration of preventive therapy post-transplantation depends on whether the patient still lives in an endemic area and on serology results. (See <a class="local">'Transplant recipients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients receiving immunomodulatory agents</strong> – We screen for coccidioidomycosis in patients who are initiating or receiving TNF alpha inhibitors or the janus kinase (JAK) inhibitor <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">ruxolitinib</a>. There are insufficient data to suggest screening for coccidioidomycosis prior to initiating other immunomodulatory drugs. We closely monitor patients who live or have lived in an endemic area for recrudescence or development of coccidioidomycosis. (See <a class="local">'Patients receiving immunomodulatory agents'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Beaman LV, Pappagianis D, Benjamini E. Mechanisms of resistance to infection with Coccidioides immitis in mice. Infect Immun 1979; 23:681.</a></li><li><a class="nounderline abstract_t">Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993; 94:235.</a></li><li><a class="nounderline abstract_t">Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis 2001; 33:1536.</a></li><li><a class="nounderline abstract_t">Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959.</a></li><li><a class="nounderline abstract_t">Fitterer C, Berg Z, Halfdanarson TR, et al. Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature. Mycopathologia 2016; 181:787.</a></li><li><a class="nounderline abstract_t">Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med 2005; 165:113.</a></li><li><a class="nounderline abstract_t">Zahid U, Shaukat AA, Hassan N, Anwer F. Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. Immunotherapy 2017; 9:1061.</a></li><li><a class="nounderline abstract_t">Vinh DC, Masannat F, Dzioba RB, et al. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis 2009; 49:e62.</a></li><li><a class="nounderline abstract_t">Sampaio EP, Hsu AP, Pechacek J, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013; 131:1624.</a></li><li><a class="nounderline abstract_t">Powers AE, Bender JM, Kumánovics A, et al. Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription. Pediatr Infect Dis J 2009; 28:664.</a></li><li><a class="nounderline abstract_t">Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis 2016; 63:e112.</a></li><li class="breakAll">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Hernández JL, Echevarría S, García-Valtuille A, et al. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16:592.</a></li><li><a class="nounderline abstract_t">Jones JL, Fleming PL, Ciesielski CA, et al. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995; 171:961.</a></li><li><a class="nounderline abstract_t">Ampel NM. Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Med Mycol 1999; 37:245.</a></li><li><a class="nounderline abstract_t">Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis 2010; 50:1.</a></li><li><a class="nounderline abstract_t">Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000; 181:1428.</a></li><li><a class="nounderline abstract_t">Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.</a></li><li><a class="nounderline abstract_t">Mortimer RB, Libke R, Eghbalieh B, Bilello JF. Immune reconstitution inflammatory syndrome presenting as superior vena cava syndrome secondary to Coccidioides lymphadenopathy in an HIV-infected patient. J Int Assoc Physicians AIDS Care (Chic) 2008; 7:283.</a></li><li><a class="nounderline abstract_t">D'Avino A, Di Giambenedetto S, Fabbiani M, Farina S. Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area. Diagn Microbiol Infect Dis 2012; 72:185.</a></li><li><a class="nounderline abstract_t">Trible R, Edgerton N, Hayek S, et al. Antiretroviral therapy-associated coccidioidal meningitis. Emerg Infect Dis 2013; 19:163.</a></li><li><a class="nounderline abstract_t">Mu A, Shein TT, Jayachandran P, Paul S. Immune Reconstitution Inflammatory Syndrome in Patients with AIDS and Disseminated Coccidioidomycosis: A Case Series and Review of the Literature. J Int Assoc Provid AIDS Care 2017; 16:540.</a></li><li><a class="nounderline abstract_t">Yaqoob H, Munawar MM, Salih O, Deonarine A. Disseminated coccidioidomycosis in a patient who is immunocompromised in the setting of immune reconstitution inflammatory syndrome. BMJ Case Rep 2021; 14.</a></li><li><a class="nounderline abstract_t">Delafield NL, Mesbah Z, Lacy CR, et al. Coccidioidomycosis in patients with various inflammatory disorders treated with tumor necrosis factor α inhibitors. Med Mycol 2021; 59:720.</a></li><li><a class="nounderline abstract_t">Bercovitch RS, Catanzaro A, Schwartz BS, et al. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis 2011; 53:363.</a></li><li><a class="nounderline abstract_t">Wack EE, Ampel NM, Galgiani JN, Bronnimann DA. Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies. Chest 1988; 94:376.</a></li><li><a class="nounderline abstract_t">Caldwell JW, Arsura EL, Kilgore WB, et al. Coccidioidomycosis in pregnancy during an epidemic in California. Obstet Gynecol 2000; 95:236.</a></li><li><a class="nounderline abstract_t">Rosenstein NE, Emery KW, Werner SB, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis 2001; 32:708.</a></li><li><a class="nounderline abstract_t">Vo A, Holmen J, Singh P. Neonatal Coccidioidomycosis: A Case Report. Pediatr Infect Dis J 2022; 41:e450.</a></li><li><a class="nounderline abstract_t">Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev 1990; 3:247.</a></li><li><a class="nounderline abstract_t">Lee BE, Feinberg M, Abraham JJ, Murthy AR. Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr Infect Dis J 1992; 11:1062.</a></li><li><a class="nounderline abstract_t">Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype. Birth Defects Res A Clin Mol Teratol 2005; 73:919.</a></li><li><a class="nounderline abstract_t">Bérard A, Sheehy O, Zhao JP, et al. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. CMAJ 2019; 191:E179.</a></li><li><a class="nounderline abstract_t">Mølgaard-Nielsen D, Svanström H, Melbye M, et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016; 315:58.</a></li><li><a class="nounderline abstract_t">Zhang Z, Zhang X, Zhou YY, et al. The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. BJOG 2019; 126:1546.</a></li><li><a class="nounderline abstract_t">Gade L, McCotter OZ, Bowers JR, et al. The detection of Coccidioides from ambient air in Phoenix, Arizona: Evidence of uneven distribution and seasonality. Med Mycol 2020; 58:552.</a></li><li><a class="nounderline abstract_t">Arguinchona HL, Ampel NM, Dols CL, et al. Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 20:1281.</a></li><li><a class="nounderline abstract_t">Saling CF, Gea-Banacloche J, Trickett JS, Blair JE. Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature. J Fungi (Basel) 2021; 7.</a></li><li><a class="nounderline abstract_t">Mendoza N, Noel P, Blair JE. Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation. Transpl Infect Dis 2015; 17:380.</a></li><li><a class="nounderline abstract_t">Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008; 21:415.</a></li><li><a class="nounderline abstract_t">Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982; 142:489.</a></li><li><a class="nounderline abstract_t">Hall KA, Sethi GK, Rosado LJ, et al. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant 1993; 12:525.</a></li><li><a class="nounderline abstract_t">Logan JL, Blair JE, Galgiani JN. Coccidioidomycosis complicating solid organ transplantation. Semin Respir Infect 2001; 16:251.</a></li><li><a class="nounderline abstract_t">Holt CD, Winston DJ, Kubak B, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997; 24:216.</a></li><li><a class="nounderline abstract_t">Hall KA, Copeland JG, Zukoski CF, et al. Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection. Transplantation 1993; 55:1422.</a></li><li><a class="nounderline abstract_t">Blair JE, Kusne S, Carey EJ, Heilman RL. The prevention of recrudescent coccidioidomycosis after solid organ transplantation. Transplantation 2007; 83:1182.</a></li><li><a class="nounderline abstract_t">Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant 2011; 11:111.</a></li><li><a class="nounderline abstract_t">Miller MB, Hendren R, Gilligan PH. Posttransplantation disseminated coccidioidomycosis acquired from donor lungs. J Clin Microbiol 2004; 42:2347.</a></li><li><a class="nounderline abstract_t">Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis 2003; 37:1265.</a></li><li><a class="nounderline abstract_t">Brugière O, Forget E, Biondi G, et al. Coccidioidomycosis in a lung transplant recipient acquired from the donor graft in France. Transplantation 2009; 88:1319.</a></li><li><a class="nounderline abstract_t">Kahn A, Carey EJ, Blair JE. Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area. Liver Transpl 2015; 21:353.</a></li><li><a class="nounderline abstract_t">Lohrmann GM, Vucicevic D, Lawrence R, et al. Single-center experience of antifungal prophylaxis for coccidioidomycosis in heart transplant recipients within an endemic area. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Chaudhary S, Meinke L, Ateeli H, et al. Coccidioidomycosis among persons undergoing lung transplantation in the coccidioidal endemic region. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Truong CN, Nailor MD, Walia R, et al. Universal Lifelong Fungal Prophylaxis and Risk of Coccidioidomycosis in Lung Transplant Recipients Living in an Endemic Area. Clin Infect Dis 2022; 74:1966.</a></li><li><a class="nounderline abstract_t">Al-Obaidi MM, Marquez J, Afghan A, Zangeneh TT. Effect of coccidioidomycosis prophylaxis in selecting non-Candida albicans species amongst solid organ transplant recipients in Arizona. Mycoses 2023; 66:237.</a></li><li><a class="nounderline abstract_t">Kusne S, Taranto S, Covington S, et al. Coccidioidomycosis Transmission Through Organ Transplantation: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee. Am J Transplant 2016.</a></li><li><a class="nounderline abstract_t">Riley DK, Galgiani JN, O'Donnell MR, et al. Coccidioidomycosis in bone marrow transplant recipients. Transplantation 1993; 56:1531.</a></li><li><a class="nounderline abstract_t">Glenn TJ, Blair JE, Adams RH. Coccidioidomycosis in hematopoietic stem cell transplant recipients. Med Mycol 2005; 43:705.</a></li><li><a class="nounderline abstract_t">Schriber J, Almond H, Alvarnas J, Sarkadee-Adoo C. Successful allogeneic bone marrow transplantation in a patient with active Coccidioidomycosis. Bone Marrow Transplant 2005; 35:927.</a></li><li><a class="nounderline abstract_t">Kusne Y, Kimes KE, Feller FF, et al. Coccidioidomycosis in Patients Treated With Ruxolitinib. Open Forum Infect Dis 2020; 7:ofaa167.</a></li><li><a class="nounderline abstract_t">Ciochetto Z, Georgen M, Hadro A, et al. Reactivation of Coccidioides immitis in a Prosthetic Knee after Initiation of Chemotherapy. Case Rep Hematol 2021; 2021:3964465.</a></li><li><a class="nounderline abstract_t">Taroumian S, Knowles SL, Lisse JR, et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2012; 64:1903.</a></li><li><a class="nounderline abstract_t">Choi K, Deval N, Vyas A, et al. The Utility of Screening for Coccidioidomycosis in Recipients of Inhibitors of Tumor Necrosis Factor α. Clin Infect Dis 2019; 68:1024.</a></li><li><a class="nounderline abstract_t">Bilal J, Kollampare S, Bode B, et al. Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases. Rheumatol Int 2019; 39:1257.</a></li></ol></div><div id="topicVersionRevision">Topic 2418 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313369" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mechanisms of resistance to infection with Coccidioides immitis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8095771" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11588699" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Coccidioidomycosis in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188373" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27492230" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642886" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Coccidioidomycosis in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032736" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681704" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23541320" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483664" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470238" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27470238" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9323471" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7706825" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Coccidioidomycosis among persons with AIDS in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421859" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995218" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753734" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440326" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18948432" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immune reconstitution inflammatory syndrome presenting as superior vena cava syndrome secondary to Coccidioides lymphadenopathy in an HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22104185" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23260018" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antiretroviral therapy-associated coccidioidal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911256" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immune Reconstitution Inflammatory Syndrome in Patients with AIDS and Disseminated Coccidioidomycosis: A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33846175" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disseminated coccidioidomycosis in a patient who is immunocompromised in the setting of immune reconstitution inflammatory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33418569" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Coccidioidomycosis in patients with various inflammatory disorders treated with tumor necrosis factorαinhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810749" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Coccidioidomycosis during pregnancy: a review and recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3396418" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Coccidioidomycosis during pregnancy. An analysis of ten cases among 47,120 pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10674586" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Coccidioidomycosis in pregnancy during an epidemic in California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229838" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35895879" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neonatal Coccidioidomycosis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2200605" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serology of coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1461702" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Congenital malformations in an infant born to a woman treated with fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16265639" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prenatal exposure to fluconazole: An identifiable dysmorphic phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782643" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746458" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31446677" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31506673" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The detection of Coccidioides from ambient air in Phoenix, Arizona: Evidence of uneven distribution and seasonality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620011" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33925759" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25682795" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594295" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039544" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Coccidioidomycosis in renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329432" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Coccidioidomycosis and heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740826" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Coccidioidomycosis complicating solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114150" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Coccidioidomycosis in liver transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8516829" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496533" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The prevention of recrudescent coccidioidomycosis after solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21087416" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Coccidioidomycosis in liver transplant recipients in an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131231" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Posttransplantation disseminated coccidioidomycosis acquired from donor lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557974" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Donor-related coccidioidomycosis in organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996932" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Coccidioidomycosis in a lung transplant recipient acquired from the donor graft in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25482428" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Universal fungal prophylaxis and risk of coccidioidomycosis in liver transplant recipients living in an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28695649" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Single-center experience of antifungal prophylaxis for coccidioidomycosis in heart transplant recipients within an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28452423" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Coccidioidomycosis among persons undergoing lung transplantation in the coccidioidal endemic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34463704" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Universal Lifelong Fungal Prophylaxis and Risk of Coccidioidomycosis in Lung Transplant Recipients Living in an Endemic Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36401812" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of coccidioidomycosis prophylaxis in selecting non-Candida albicans species amongst solid organ transplant recipients in Arizona.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27376472" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Coccidioidomycosis Transmission Through Organ Transplantation: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8279031" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Coccidioidomycosis in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16422300" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Coccidioidomycosis in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15778732" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Successful allogeneic bone marrow transplantation in a patient with active Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548203" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Coccidioidomycosis in Patients Treated With Ruxolitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34970462" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reactivation of Coccidioides immitis in a Prosthetic Knee after Initiation of Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22745051" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30084971" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The Utility of Screening for Coccidioidomycosis in Recipients of Inhibitors of Tumor Necrosis Factorα.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31065743" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Management of asymptomatic coccidioidomycosis in patients with rheumatic diseases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
